ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Interferon Treatment For MS Reduces Lesions In About Half Of Patients
According to an article published early online and in the January 2009
issue of Archives of Neurology,
about half of multiple sclerosis (MS) patients who are treated with
three years of interferon beta are able to achieve and sustain a
response as measured by regular
magnetic resonance imaging (MRI) evaluations.
Researcher Annie
W.
Chiu, B.S. (National Institute of Neurological
Disorders and Stroke, Bethesda, Md.) and colleagues make use of that
fact that MS patients develop contrast-enhancing brain lesions that
MRIs can detect before the patient presents relapse symptoms. The
disease is believed to get worse after these relapses. "Many clinical
studies
have demonstrated the ability of interferon beta to reduce
contrast-enhancing lesions," write the researchers. "However, little is
known regarding the heterogeneity of the MRI response profiles between
patients or within an individual patient over time."
Chiu and
colleagues studied 15 MS patients who received monthly MRIs and
clinical examinations during two treatment periods. The first was a
6-month
pretreatment phase, and the second was a 36-month treatment phase where
each patient received 250-microgram injections of interferon beta under
the skin every other day.
The study resulted in 8 patients
(53.3%) classified as responders due to their 60% reduction in the
number of lesions found at each six-month
period. The seven non-responders, however, consisted of three who
experienced only a brief period of lesion reduction followed by no
further reduction and two who never met the 60% percent level of
reduction during the 6-month treatment period but reached and
maintained a 60% or more reduction afterward. The researchers also
noted at least one clinical exacerbation during the treatment face in
three responder-group patients and
in all seven patients in the non-responder group.
"To our
knowledge, our descriptive study provides for the first time a detailed
long-term analysis of MRI patterns of patients undergoing long-term
interferon beta-1b therapy," conclude Chiu and colleagues. "The results
show
that on close monthly MRI inspection, approximately half of the
patients fail therapy from an MRI perspective."
The researchers add: "Also, we show
that an additional small proportion of patients may not be necessarily
recognized as MRI non-responders during the first semester [six months]
of therapy, and frequent radiological monitoring is advised during the
first year of therapy. Multiple MRIs, beyond the first six months of
therapy, also disclose a small proportion of patients with a delayed
but eventually sustained response to interferon beta and provide
compelling information regarding the clinical outcome of patients
during the course of a longer trial."
Heterogeneity in Response to Interferon Beta in Patients With
Multiple Sclerosis
Annie W. Chiu, BS; Nancy Richert, MD, PhD; Mary Ehrmantraut,
MS;
Joan Ohayon, MSN; Shiva Gupta, MD; Giuseppe Bomboi, MD; Deeya Gaindh,
AB; Fredric K. Cantor, MD; Joseph A. Frank, MS, MD; Henry F. McFarland,
MD; Francesca Bagnato, MD, PhD
Archives of Neurology (2008). 66[1].
doi:10.1001/archneur.66.1.noc80047
Click
Here to View Abstract
Written by: Peter M Crosta
Copyright: Start Sanatate
Not to be reproduced without permission of Start Sanatate
Interferon tratament pentru MS Reduce leziuni În aproximativ jumãtate din pacienþii - Interferon Treatment For MS Reduces Lesions In About Half Of Patients - articole medicale engleza - startsanatate